Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Toovey

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Drug Safety|November 26, 2008
Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive reviewStephen Toovey, Craig Rayner, Eric Prinssen, et al.
The Journal of Infectious Diseases|August 29, 2012
Determinants of antiviral effectiveness in influenza virus A subtype H5N1Paul K S Chan, Nelson Lee, Mukhtiar Zaman, et al.
Journal of Infection in Developing Countries|February 13, 2014
Recognizing true H5N1 infections in humans during confirmed outbreaksMukhtiar Zaman, Viktor Gasimov, Ahmet Faik Oner, et al.
British Journal of Clinical Pharmacology|February 9, 2017
Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemicsMohamed A Kamal, Patrick F Smith, Nathorn Chaiyakunapruk, et al.
Influenza and Other Respiratory Viruses|July 28, 2023
Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: A phase 2 proof-of-concept trialLi-Min Huang, Andreas Schibler, Yi-Chuan Huang, et al.
The Lancet. Infectious Diseases|June 18, 2018
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a studyAlejandro Llanos-Cuentas, Martin Casapia, Raúl Chuquiyauri, et al.
Environmental Health Perspectives|December 6, 2008
Meeting report: risk assessment of tamiflu use under pandemic conditionsAndrew C Singer, Bruce M Howard, Andrew C Johnson, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Drug Safety|November 26, 2008
Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive reviewStephen Toovey, Craig Rayner, Eric Prinssen, et al.
The Journal of Infectious Diseases|August 29, 2012
Determinants of antiviral effectiveness in influenza virus A subtype H5N1Paul K S Chan, Nelson Lee, Mukhtiar Zaman, et al.
Journal of Infection in Developing Countries|February 13, 2014
Recognizing true H5N1 infections in humans during confirmed outbreaksMukhtiar Zaman, Viktor Gasimov, Ahmet Faik Oner, et al.
British Journal of Clinical Pharmacology|February 9, 2017
Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemicsMohamed A Kamal, Patrick F Smith, Nathorn Chaiyakunapruk, et al.
Influenza and Other Respiratory Viruses|July 28, 2023
Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: A phase 2 proof-of-concept trialLi-Min Huang, Andreas Schibler, Yi-Chuan Huang, et al.
The Lancet. Infectious Diseases|June 18, 2018
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a studyAlejandro Llanos-Cuentas, Martin Casapia, Raúl Chuquiyauri, et al.
Environmental Health Perspectives|December 6, 2008
Meeting report: risk assessment of tamiflu use under pandemic conditionsAndrew C Singer, Bruce M Howard, Andrew C Johnson, et al.
Pageof 6